NASOX is developed by Asan Medical Center.

What development phase is NASOX in?

NASOX is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

NASOX

Asan Medical Center · FDA-approved active Small molecule Quality 4/100

At a glance

Generic name	NASOX
Sponsor	Asan Medical Center
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma (PHASE1,PHASE2)
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NASOX CI brief — competitive landscape report
NASOX updates RSS · CI watch RSS
Asan Medical Center portfolio CI